SLYND Drug Patent Profile
✉ Email this page to a colleague
When do Slynd patents expire, and when can generic versions of Slynd launch?
Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-six patent family members in twenty-nine countries.
The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.
DrugPatentWatch® Generic Entry Outlook for Slynd
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 28, 2031. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SLYND?
- What are the global sales for SLYND?
- What is Average Wholesale Price for SLYND?
Summary for SLYND
International Patents: | 66 |
US Patents: | 14 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Patent Applications: | 2,065 |
Drug Prices: | Drug price information for SLYND |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SLYND |
What excipients (inactive ingredients) are in SLYND? | SLYND excipients list |
DailyMed Link: | SLYND at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SLYND
Generic Entry Date for SLYND*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Paragraph IV (Patent) Challenges for SLYND
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SLYND | Tablets | drospirenone | 4 mg | 211367 | 1 | 2022-01-07 |
US Patents and Regulatory Information for SLYND
SLYND is protected by fourteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SLYND is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SLYND
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SLYND
When does loss-of-exclusivity occur for SLYND?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1670
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 11273605
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2012033391
Estimated Expiration: ⤷ Sign Up
Patent: 2019008317
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 03721
Estimated Expiration: ⤷ Sign Up
Patent: 03062
Estimated Expiration: ⤷ Sign Up
Patent: 61421
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 12003685
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 40328
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0200155
Estimated Expiration: ⤷ Sign Up
Patent: 0220332
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 22544
Estimated Expiration: ⤷ Sign Up
Patent: 25061
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 12012359
Estimated Expiration: ⤷ Sign Up
Patent: 15032906
Estimated Expiration: ⤷ Sign Up
Patent: 15032911
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8680
Estimated Expiration: ⤷ Sign Up
Patent: 1291372
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Patent: 56186
Estimated Expiration: ⤷ Sign Up
France
Patent: C1020
Estimated Expiration: ⤷ Sign Up
Patent: C1031
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1200336
Estimated Expiration: ⤷ Sign Up
Patent: 1200336A
Estimated Expiration: ⤷ Sign Up
Patent: 1200336B
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 47689
Estimated Expiration: ⤷ Sign Up
Patent: 58176
Estimated Expiration: ⤷ Sign Up
Patent: 000016
Estimated Expiration: ⤷ Sign Up
Patent: 200018
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 10159
Estimated Expiration: ⤷ Sign Up
Patent: 13529665
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 2021523
Estimated Expiration: ⤷ Sign Up
Patent: 2022513
Estimated Expiration: ⤷ Sign Up
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 9952
Estimated Expiration: ⤷ Sign Up
Patent: 4971
Estimated Expiration: ⤷ Sign Up
Patent: 12014629
Estimated Expiration: ⤷ Sign Up
Patent: 19004393
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5176
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 20015
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 130780
Estimated Expiration: ⤷ Sign Up
Patent: 161410
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 826
Estimated Expiration: ⤷ Sign Up
Patent: 027
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1209743
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2164693
Estimated Expiration: ⤷ Sign Up
Patent: 2210982
Estimated Expiration: ⤷ Sign Up
Patent: 2539030
Estimated Expiration: ⤷ Sign Up
Patent: 130048227
Estimated Expiration: ⤷ Sign Up
Patent: 170085604
Estimated Expiration: ⤷ Sign Up
Patent: 190073598
Estimated Expiration: ⤷ Sign Up
Patent: 210013663
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 77886
Estimated Expiration: ⤷ Sign Up
Patent: 08657
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SLYND around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2777886 | ⤷ Sign Up | |
Brazil | 122019008317 | ⤷ Sign Up | |
Denmark | 3632448 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SLYND
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3632448 | C202230031 | Spain | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONA; NATIONAL AUTHORISATION NUMBER: 84603-SE/H/1869/001/DC; DATE OF AUTHORISATION: 20191025; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SE/H/1809/001/DC; DATE OF FIRST AUTHORISATION IN EEA: 20191016 |
2588114 | 122021000065 | Germany | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON; NAT. REGISTRATION NO/DATE: 7002248.00.00 20210426; FIRST REGISTRATION: DK 61678 20191016 |
3632448 | PA2022513 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONAS; REGISTRATION NO/DATE: LT/1/21/4721/001-004 20210419 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |